It's not about being right, it's about making money. There's a difference and I think that gets forgotten too often. We want to position ourselves where we have the highest probabilities for success as well as where the risk vs reward is skewed in our...
If you've been reading our blog for a while, you're probably familiar with our process and how we identify reward/risk scenarios that are ridiculously skewed in our favor. With that said, the way we accomplish that doesn't always look exactly the same...
Life isn't just about Tesla gossip and Apple at a trillion. There is plenty of "less sexy" market behavior to be paying attention to right now that should have serious implications for the overall market. While boring to some, we have a huge...
This entire year we've been talking about under-performance in the mid-cap and small-cap segments of the market. To take advantage of that we've wanted to be shorting, or at least avoiding longs in, the weakest names in sectors like Public Sector...
There's been a lot of talk about equity market breadth both in the US and globally, but one thing I've not seen mentioned throughout the debate is Dow Theory. While there are...
Sector rotation in this market continues and the Agribusiness and Chemical Industries within the Materials Sector look to be heating up. While their performance on a relative basis is...
Every so often we hear the narrative that under-performance from China's stock market is a canary in the coal mine for US Equities, and the recent tariff tantrums have brought this discussion...
We've been extremely vocal about the Medical Devices space on the blog, and rightfully so, with the sector continuing its long-term trend of out-performance throughout 2018. The index has 57...
Most Nifty Indexes' largest components have a very large weighting on their performance, and Nifty Pharma is no exception. Sun Pharmaceuticals represents roughly a quarter of the index, so today we're going to look at it's role as a potential leading...
Interest rates are on the move, with the Ten-Year Treasury Yield breaking 3% once again after working off its failed breakout attempt from May. One relationship that's highly correlated with...
It's the end of the month, which means we've got new monthly charts. Last month we discussed the strength in large-cap Financial Services, Consumer Goods, IT, and in certain areas of Pharma, while the weakest areas were mid and small-cap...
Based on the great feedback we receive every day, we know a lot of Allstarcharts India readers have an interest in the mid-cap and small-cap segments of the market. Typically we cover those areas in the...
When I thought of the title for this post I was hoping to make a Nascar analogy, but quickly realized I don't know anything about Nascar or racing. With that aside, what's clear from our...
This weekend all of the Chartbooks on the site were updated, so this is a quick post to highlight some of the significant developments since they were last updated.
The broad-based Financials ETF $XLF has gone basically sideways for the majority of the year, but under the surface there has been strength in individual names and sub-sectors like Broker-...
The Nasdaq Composite closed at another all-time high yesterday, but some are questioning this rally's sustainability due to the under-performance of the Semiconductor Index. Given we're open-...
This week I was in New York meeting with partners and old friends. On Tuesday I was down at the Bloomberg Headquarters chatting with Catherine Murray about what we're seeing from a technical perspective. We discuss Technology, Medical Equipment stocks...
Over the last week or so we've seen an upside reversal in many of the Public Sector Bank stocks across the large, mid, and small-cap segments of the market. This has many wondering whether or not this is "the bottom" in this sector or if it's simply "...